Praxis reports Q1 net loss of $92.6M; FDA accepts NDAs for ulixacaltamide and relutrigine

Praxis Precision Medicines, Inc.

2026-Q1 EPS reported -$3.20 vs consensus -$3.62 ▲ beat (+11.6%)

FDA accepted NDA for ulixacaltamide (Essential Tremor) with PDUFA Jan 29, 2027; relutrigine NDA (SCN2A/SCN8A DEEs) granted priority review with PDUFA Sept 27, 2026.
Cash and investments $1.4B as of Mar 31, 2026, up from $926.1M Dec 2025; funded into 2028.
Net loss $92.6M vs $69.3M in Q1 2025; R&D expenses $78.0M (up $17.2M YoY); G&A $27.9M (up $14.0M YoY).
EMBRAVE Part A: elsunersen showed 77% placebo-adjusted seizure reduction; 71% patients achieved >50% reduction.
Topline POWER1 (vormatrigine in FOS) expected Q2 2026; EMERALD (relutrigine in broad DEEs) topline Q4 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Praxis Precision Medicines, Inc. reported financial results for the first quarter of 2026.

Period: the first quarter of 2026
Result: reported results

Exact text from the filing

Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Praxis Precision Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001689548-26-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.